Sanofi has taken another step on the path to becoming the world’s leading immunology company by paying $600m to acquire Dren Bio’s DR-0201, an early-stage bispecific myeloid cell engager.
Sanofi Advances Immunology Ambitions With Dren Deal
The France-based giant inks a transaction potentially worth around $1.9bn to get hold of Dren Bio’s autoimmune disease treatment DR-0201.
